Literature DB >> 32300833

A rare case of polyostotic fibrous dysplasia detected on 18F-rhPSMA-7 PET/CT.

Hui Wang1, Matthias Eiber2, Thomas Langbein1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32300833      PMCID: PMC7567679          DOI: 10.1007/s00259-020-04751-9

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


× No keyword cloud information.
The prostate-specific membrane antigen (PSMA) has been proven to show high expression in prostate cancer cells [1]. The high binding affinity and internalization of PSMA radioligands makes it an excellent molecular target for theranostics of prostate cancer [1]. Positron emission tomography/computed tomography (PET/CT) using novel PSMA-targeting probes is increasingly used in recurrent and metastastic prostate cancer [2]. In addition, it is increasingly being used as an imaging modality for initial staging [3]. 18F-rhPSMA-7 is a new theranostic PSMA-targeting agent which allows radiolabeling with 18F and radiometals and is associated with minimal renal excretion [4]. However, physiologic and other pathologic forms of tracer uptake have to be considered carefully as potential pitfalls to image interpretation, such as ganglia, healing fracture, adrenal adenoma, primary lung cancer, and metastatic renal cell carcinoma [5]. Fibrous dysplasia is an uncommon skeletal disorder, accounting for 5 to 7% of all benign bone tumors [6]. Around 75% of cases have a monostotic form with only one bone involved, commonly the craniofacial bones, but the ribs, femur, and tibia may also be involved [7, 8]. PSMA-ligand uptake has been reported in monostotic (rib) fibrous dysplasia using 68Ga-PSMA-PET/CT, and this has to be differentiated from prostate cancer bone metastases [9]. Here, we present a case of uncommon polyostotic fibrous dysplasia identified on PSMA PET/CT imaging. An 80-year-old man with histologically confirmed prostate cancer (Gleason score 7a, iPSA 4.26 ng/mL) by transurethral resection of the prostate (TUR-P) performed in February 2018 underwent 18F-rhPSMA-7 PET/CT imaging for staging in October 2018. No focal uptake in the prostate bed and no evidence of pelvic lymph node metastases was seen. However, intense tracer uptake was observed in the right parietal skull, in the left 3rd, 8th, and 9th ribs, and in the left ilium (red arrows in a MIP and d + e PET). The corresponding bone scan performed 2 weeks earlier had shown hypermetabolic lesions in the same areas (b bone scan). Finally, typical CT morphologic findings, including expansive changes with ground-glass appearance, cortical erosion, diffuse sclerosis, and well-circumscribed margins could be observed and, therefore, clearly confirmed radiologically polyostotic fibrous dysplasia (c CT) [10]. This case indicates that a thorough review of the CT dataset of a hybrid PSMA-ligand PET/CT is not only useful to correctly identify solitary or isolated lesions but also mandatory to avoid a potential pitfall and correctly differentiate extensive polyostotic fibrous dysplasia from metastatic bone lesions [11] when PSMA-ligand uptake in the bone is seen.
  10 in total

1.  Imaging findings of fibrous dysplasia with histopathologic and intraoperative correlation.

Authors:  Kimberly A Fitzpatrick; Mihra S Taljanovic; Donald P Speer; Anna R Graham; Jon A Jacobson; George R Barnes; Tim B Hunter
Journal:  AJR Am J Roentgenol       Date:  2004-06       Impact factor: 3.959

2.  Fibrous dysplasia mimicking bone metastasis on 68GA-PSMA PET/MRI.

Authors:  Liesbeth De Coster; Raf Sciot; Wouter Everaerts; Olivier Gheysens; Raf Verscuren; Christophe M Deroose; Steven Pans; Koen Van Laere; Karolien E Goffin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-09       Impact factor: 9.236

Review 3.  Fibrous dysplasia.

Authors:  Nicole D Riddle; Marilyn M Bui
Journal:  Arch Pathol Lab Med       Date:  2013-01       Impact factor: 5.534

Review 4.  Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.

Authors:  Andrea Farolfi; Wolfgang Fendler; Amir Iravani; Uwe Haberkorn; Rodney Hicks; Ken Herrmann; Jochen Walz; Stefano Fanti
Journal:  Eur Urol Oncol       Date:  2019-01-31

5.  Heterogeneity of 68Ga-PSMA PET/CT Uptake in Fibrous Dysplasia.

Authors:  Nicolas Plouznikoff; Camilo Garcia; Carlos Artigas; Kim Entezari; Patrick Flamen
Journal:  Clin Nucl Med       Date:  2019-10       Impact factor: 7.794

6.  Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of a Novel Radiohybrid PSMA, 18F-rhPSMA-7, in Patients with Prostate Cancer.

Authors:  So Won Oh; Alexander Wurzer; Eugene J Teoh; Sohee Oh; Thomas Langbein; Markus Krönke; Michael Herz; Saskia Kropf; Hans-Jürgen Wester; Wolfgang A Weber; Matthias Eiber
Journal:  J Nucl Med       Date:  2019-12-13       Impact factor: 10.057

Review 7.  Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.

Authors:  Sara Sheikhbahaei; Ali Afshar-Oromieh; Matthias Eiber; Lilja B Solnes; Mehrbod S Javadi; Ashley E Ross; Kenneth J Pienta; Mohamad E Allaf; Uwe Haberkorn; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-01       Impact factor: 9.236

Review 8.  The nature of fibrous dysplasia.

Authors:  Liviu Feller; Neil H Wood; Razia A G Khammissa; Johan Lemmer; Erich J Raubenheimer
Journal:  Head Face Med       Date:  2009-11-09       Impact factor: 2.151

9.  18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.

Authors:  Jeremie Calais; Francesco Ceci; Matthias Eiber; Thomas A Hope; Michael S Hofman; Christoph Rischpler; Tore Bach-Gansmo; Cristina Nanni; Bital Savir-Baruch; David Elashoff; Tristan Grogan; Magnus Dahlbom; Roger Slavik; Jeannine Gartmann; Kathleen Nguyen; Vincent Lok; Hossein Jadvar; Amar U Kishan; Matthew B Rettig; Robert E Reiter; Wolfgang P Fendler; Johannes Czernin
Journal:  Lancet Oncol       Date:  2019-07-30       Impact factor: 41.316

Review 10.  Benign tumours of the bone: A review.

Authors:  David N Hakim; Theo Pelly; Myutan Kulendran; Jochem A Caris
Journal:  J Bone Oncol       Date:  2015-03-02       Impact factor: 4.072

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.